AN INJECTABLE HIV-PREVENTION DRUG IS HIGHLY EFFECTIVE — BUT WILDLY EXPENSIVE

Summary from the TLDR newsletter

The results from a landmark pair of major clinical trials of lenacapavir, an injectable HIV-prevention drug that only requires dosing every six months, show that it is 89% more effective at preventing HIV than daily oral preventative medication among gay, bisexual, and transgender people. It could be a game changer if rolled out broadly and equitably, but the drug is extraordinarily expensive. Its current list price for use as an HIV treatment is $3,450 per month. It is unclear whether it will have a different list price for use as a preventive.